Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03913832
Other study ID # 180013
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date August 28, 2020
Est. completion date September 10, 2023

Study information

Verified date October 2022
Source Concept Medicals BV
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study is a prospective, multinational (Italy, Ireland and UK), multicenter, randomised Clinical Trial that compares the efficacy and performance of two drug coated balloon (DCB), the MAGIC TOUCH sirolimus coated balloon (Concept Medical) and SeQuent Please paclitaxel coated balloon (B Braun). The objective of the study is to compare angiographic outcomes of Magic TouchTM sirolimus coated balloon (Concept Medical) versus SeQuentTM paclitaxel coated balloon (Bbraun) for the treatment of de novo coronary artery lesions in small vessels (≤2.75 mm) with respect to Net Gain (mm) at 6 months follow-up


Description:

A prospective, randomized, multi-centre study in subjects with small vessels, i.e. at least one de-novo lesion in a small vessel (≤2.75mm). Vessel size will be determined first by QCA on-line (screening, pre-procedure). If, based on QCA on-line the vessel size pre-procedure is ≤2.75mm and following a successful pre-dilatation (i.e. no angiographic dissections type CDEF and TIMI>2), the subject will be randomized in a 1:1 fashion to Magic Touch or SeQuent Please Neo. OCT will be performed post pre-dilatation (guidance) prior to drug coated balloon (DCB) treatment. The DCB balloon size will be selected based on OCT measurements.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 121
Est. completion date September 10, 2023
Est. primary completion date March 10, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Male or female patients =18 years 2. Patient with chronic stable angina or stabilized acute coronary syndromes with normal cardiac biomarker values Note: For patients showing elevated Troponin (e.g. non-STEMI patients) at baseline (within 72h pre-PCI) an additional blood sample must be collected prior to randomization to confirm that: - hs-cTn or Troponin I or T levels are stable, i.e. the value should be within 20% range of the value found in the first sample at baseline, or have dropped - CK-MB and CK levels are within normal range If hs-cTn or Troponin I or T levels are stable or have dropped, the CK-MB and CK levels are within normal ranges, and the ECG is normal, the patient may be included in the study. 3. The patient has a planned intervention in one or two separate major epicardial territories (LAD, LCX or RCA) and has at least one de-novo lesion in a small vessel (=2.75mm by QCA prior to pre-dilatation) 4. Target lesion length =30 mm 5. Able to understand and provide informed consent and comply with all study procedures including 6 months angiographic follow-up 6. Patient must have completed the follow-up phase of any previous study Exclusion Criteria: 1. Patient is a woman who is pregnant or nursing (a pregnancy test must be performed within 7 days prior to the index procedure in women of child-bearing potential) 2. Evidence of ongoing acute myocardial infarction (AMI) in ECG and/or elevated cardiac biomarkers (according to local standard hospital practice) have not returned within normal limits at the time of procedure 3. Known contraindication or hypersensitivity to sirolimus, paclitaxel, or to medications such as aspirin, heparin, and all of the following four medications: clopidogrel bisulfate, ticlopidine, prasugrel, ticagrelor 4. Patient suffered from stroke/TIA during the last 6 months 5. LVEF <30% 6. Platelet count <100,000 cells/mm3 or >400,000 cells/mm3, a WBC of <3,000 cells/mm3, or documented or suspected liver disease (including laboratory evidence of hepatitis) 7. Known renal insufficiency (e.g. serum creatinine >2.5mg/dL, or creatinine clearance =30 mL/min), or subject on dialysis, or acute kidney failure (as per physician judgment) 8. Patient undergoing planned surgery within 6 months with the necessity to stop DAPT 9. History of bleeding diathesis or coagulopathy 10. The patient is a recipient of a heart transplant 11. Concurrent medical condition with a life expectancy of less than 12 months 12. The patient is unwilling/not able to return for angiographic recatherisation at 6 month follow-up 13. Currently participating in another trial and not yet at its primary endpoint. Angiographic exclusion criteria: 14. The patient has a planned intervention in three separate major epicardial territories (3 vessel disease) 15. The patient has a planned intervention in the left-main plus two separate major epicardial territories (left-main plus 2 vessel disease) 16. Target vessel size >2.75 mm (by QCA) 17. Target vessel size <2.00 mm (by QCA) 18. Target lesion has a total occlusion or TIMI flow <2 19. Target lesion in left main stem 20. The target vessel contains visible thrombus 21. Aorto-ostial target lesion (within 3 mm of the aorta junction) 22. Moderate-severe tortuous, calcified or angulated coronary anatomy of the target vessel that in the opinion of the investigator would result in suboptimal imaging or excessive risk of complication from placement of an OCT catheter 23. Lesion is located within an arterial or saphenous vein graft or distal to a diseased arterial or saphenous vein graft.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
sirolimus drug coated balloon (SCB)
Magic TouchTM (Concept Medical) is a sirolimus drug coated balloon (SCB) for PCI, based on a polymer-free and Nano based drug delivery technology. Magic Touch SCB is a product of CMI proprietary drug delivery technology "Nanolute". It is indicated (CE approved) for ISR, small vessels, bifurcation lesions & de novo lesions.
paclitaxel releasing coronary balloon catheter
SeQuent PleaseTM (B. Braun Melsungen AG, Vascular Systems,Berlin, Germany) is a paclitaxel releasing coronary balloon catheter.

Locations

Country Name City State
Ireland Galway University Hospital Galway
Italy Maria Cecilia Hospital spa Cotignola Emilia-Romagna
Italy AOUC Azienda Ospedaliero-Universitaria Careggi Firenze Tuscany
Italy Istituto Clinico Humanitas Rozzano
Italy I.R.C.C.S. Policlinico San Donato San Donato Milanese Lombardy
United Kingdom Heart of England NHS Trust, Heartlands Hospital Birmingham

Sponsors (1)

Lead Sponsor Collaborator
Concept Medicals BV

Countries where clinical trial is conducted

Ireland,  Italy,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Net Gain (mm) In-segment The primary endpoint is in-segment (balloon treated area) Net Gain (mm) at 6 months post-procedure. 6 Months
Secondary Device success Successful delivery and inflation within 45 seconds of the allocated DCB device at the intended target lesion during an attempt with a DCB not previously used (first use) and successful withdrawal of the device system with attainment of final in-lesion residual stenosis of <30% (by Quantitative Coronary angiography). Post procedure (Right after the treatment with drug coated balloon)
Secondary Procedure Success Successful delivery and inflation within 45 seconds of the allocated DCB device at all intended target lesion(s) during an attempt with a DCB not previously used (first use) and successful withdrawal of the device system with attainment of final in-lesion residual stenosis of <30% (by QCA) without the occurrence of TLF during the index procedure hospital stay). Post procedure (Right after the treatment with drug coated balloon)
Secondary Acute/subacute/early/late vessel closure/thrombosis Closure by restenosis or thrombosis (diameter stenosis of 100% and/or TIMI grade 0). 1, 6 months and 12 Months
Secondary Angiographic outcomes: late lumen loss The difference between the minimum lumen diameter (MLD) immediately after index procedure and the MLD at follow-up as measured in (preferable) identical orthogonal views (MLDpost - MLDfup). 6 months
Secondary Angiographic outcomes:Minimal lumen diameter The smallest lumen diameter in the segment of interest 6 months
Secondary Angiographic outcomes: Percent diameter stenosis The percentage of luminal narrowing of vessel segment of interest 6 months
Secondary Angiographic outcomes: Restenosis rate Restenosis is defined as =50% diameter stenosis at follow-up. 6 months
Secondary Device oriented Composite Endpoint (DoCE / TLF): Cardiac death Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all study procedure related deaths including those related to concomitant treatment. 1, 6 months and 12 Months
Secondary Device oriented Composite Endpoint (DoCE / TLF): Target vessel: myocardial infarction (TV-MI) The term myocardial injury should be used when there is evidence of elevated cardiac troponin values (cTn) with at least one value above the 99th percentile upper reference limit (URL) TV-MI: Myocardial Infarction not clearly attributable to a non-target vessel. 1, 6 months and 12 Months
Secondary Device oriented Composite Endpoint (DoCE / TLF): clinically indicated target lesion revascularization(TLR) TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. 1, 6 months and 12 Months
See also
  Status Clinical Trial Phase
Recruiting NCT06030596 - SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
Completed NCT04080700 - Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
Recruiting NCT03810599 - Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study N/A
Recruiting NCT06002932 - Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions. N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT04242134 - Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions N/A
Recruiting NCT05308719 - Nasal Oxygen Therapy After Cardiac Surgery N/A
Completed NCT04556994 - Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients. N/A
Recruiting NCT05846893 - Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease N/A
Recruiting NCT06027788 - CTSN Embolic Protection Trial N/A
Recruiting NCT05023629 - STunning After Balloon Occlusion N/A
Completed NCT04941560 - Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
Completed NCT04006288 - Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease Phase 4
Completed NCT01860274 - Meshed Vein Graft Patency Trial - VEST N/A
Recruiting NCT06174090 - The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients N/A
Completed NCT03968809 - Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
Terminated NCT03959072 - Cardiac Cath Lab Staff Radiation Exposure
Recruiting NCT05065073 - Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography Phase 4
Recruiting NCT04566497 - Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up. N/A
Completed NCT05096442 - Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions N/A

External Links